Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ascendis Pharma AS Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Ascendis Pharma AS Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Mar 2022 | Lorem |
| LoA Update: Ascendis Pharma’s achondroplasia asset ACP-015 sees its trial advancement potential grow after positive interim Phase II data reveal | 22 Dec 2021 | Adam Zamecnik |
| Opko, Novo Nordisk and Ascendis’ long-acting growth hormones for paediatric growth hormone deficiency lack pricing premium argument, experts say | 06 Feb 2019 | Mina Moawad,Jennifer C. Smith-Parker |
| Ascendis' Phase III TransCon GH program has fewer than typical 6-12% rate of non-neutralizing antibodies - exec | 11 Jan 2018 | Jennifer C. Smith-Parker |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer